These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16685647)

  • 21. Loss of heterozygosity analysis in ductal lavage samples from BRCA1 and BRCA2 carriers: a cautionary tale.
    Antill YC; Mitchell G; Johnson SA; Devereux L; Milner A; Phillips KA; Campbell IG
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1396-8. PubMed ID: 16835342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers.
    Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
    J Appl Genet; 2009; 50(4):379-84. PubMed ID: 19875889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
    Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
    J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions.
    Kurose K; Hoshaw-Woodard S; Adeyinka A; Lemeshow S; Watson PH; Eng C
    Hum Mol Genet; 2001 Sep; 10(18):1907-13. PubMed ID: 11555627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors.
    Gras E; Cortes J; Diez O; Alonso C; Matias-Guiu X; Baiget M; Prat J
    Cancer; 2001 Aug; 92(4):787-95. PubMed ID: 11550149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
    Esteller M; Silva JM; Dominguez G; Bonilla F; Matias-Guiu X; Lerma E; Bussaglia E; Prat J; Harkes IC; Repasky EA; Gabrielson E; Schutte M; Baylin SB; Herman JG
    J Natl Cancer Inst; 2000 Apr; 92(7):564-9. PubMed ID: 10749912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.
    Rio PG; Pernin D; Bay JO; Albuisson E; Kwiatkowski F; De Latour M; Bernard-Gallon DJ; Bignon YJ
    Int J Oncol; 1998 Oct; 13(4):849-53. PubMed ID: 9735416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
    Gao X; Porter AT; Honn KV
    Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
    Gaffney DK; Hemmersmeier J; Holden J; Marshall J; Smith LM; Avizonis V; Tran T; Neuhausen SL
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):539-46. PubMed ID: 11173152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
    Charef-Hamza S; Trimeche M; Ziadi S; Amara K; Gaddas N; Mokni M; Sriha B; Yacoubi T; Korbi S
    Cancer Lett; 2005 Jun; 224(2):185-91. PubMed ID: 15914269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome.
    Wistuba II; Tomlinson GE; Behrens C; Virmani A; Geradts J; Blum JL; Minna JD; Gazdar AF
    Genes Chromosomes Cancer; 2000 Aug; 28(4):359-69. PubMed ID: 10862044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis.
    Xu B; Hamada S; Kusuki I; Itoh R; Kitawaki J
    Gynecol Oncol; 2011 Feb; 120(2):239-46. PubMed ID: 21130491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.
    Shen CY; Yu JC; Lo YL; Kuo CH; Yue CT; Jou YS; Huang CS; Lung JC; Wu CW
    Cancer Res; 2000 Jul; 60(14):3884-92. PubMed ID: 10919664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical management of women with genomic BRCA1 and BRCA2 mutations.
    Chang J; Elledge RM
    Breast Cancer Res Treat; 2001 Sep; 69(2):101-13. PubMed ID: 11759816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.
    Tseng SL; Yu IC; Yue CT; Chang SF; Chang TM; Wu CW; Shen CY
    Genes Chromosomes Cancer; 1997 Dec; 20(4):377-82. PubMed ID: 9408754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer.
    Silva JM; Gonzalez R; Provencio M; Dominguez G; Garcia JM; Gallego I; Palacios J; España P; Bonilla F
    Breast Cancer Res Treat; 1999 Jan; 53(1):9-17. PubMed ID: 10206068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.
    Godwin AK; Vanderveer L; Schultz DC; Lynch HT; Altomare DA; Buetow KH; Daly M; Getts LA; Masny A; Rosenblum N
    Am J Hum Genet; 1994 Oct; 55(4):666-77. PubMed ID: 7942844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors.
    Tong D; Kucera E; Schuster E; Schmutzler RK; Swoboda H; Reinthaller A; Leodolter S; Zeillinger R
    Int J Cancer; 2000 Oct; 88(2):319-22. PubMed ID: 11004687
    [No Abstract]   [Full Text] [Related]  

  • 40. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.
    Wang ZC; Buraimoh A; Iglehart JD; Richardson AL
    Breast Cancer Res Treat; 2006 Jun; 97(3):301-9. PubMed ID: 16791486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.